Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Condition:   Head and Neck Cancer
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Procedure: Standard of Care Surgery
Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
Not yet recruiting - verified September 2016

http://ift.tt/2dxRMPR


http://ift.tt/2daUyrI